Table II.
Antihypertensive and Other Medication Taken by Study Participants
| Young‐Old | Older‐Old | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SDH | ISH | SDH | ISH | |||||||||
| Weeks | 0 (n=l40) | 12 (n=126) | 24 (n=122) | 0 (n=l40) | 12 (n=134) | 24 (n=130) | 0 (n=109) | 12 (n=95) | 24 (n=87) | 0 (n=161) | 12 (n=153) | 24 (n=l42) |
| OLM dose, mg | 9.7±3.2 | 11.9±4.9 | 12.3±4.9 | 10.1±4.2 | 12.1±5.9 | 12.6±6.6 | 6.8±3.4 | 10.3±4.5 | 10.7±4.9 | 6.6±3.0 | 10.6±5.2 | 11.4±5.7 |
| 5 mg | 24 (17.1) | 13 (10.3) | 9 (7.4) | 22 (15.7) | 9 (6.7) | 10 (7.7) | 78 (71.6) | 22 (23.2) | 19 (21.8) | 117 (72.7) | 45 (29.4) | 38 (26.8) |
| 10 mg | 108 (77.1) | 82 (65.1) | 80 (65.6) | 107 (76.4) | 99 (73.9) | 89 (68.5) | 27 (24.8) | 59 (62.1) | 52 (59.8) | 40 (24.8) | 77 (50.3) | 65 (45.8) |
| 20 mg | 8 (5.7) | 31 (24.6) | 33 (27.0) | 10 (7.1) | 23 (17.2) | 27 (20.8) | 4 (3.7) | 14 (14.7) | 16 (18.4) | 4 (2.5) | 31 (20.3) | 39 (27.5) |
| 40 mg | 0 (0) | 0 (0) | 0 (0) | 1 (0.7) | 3 (2.2) | 4 (3.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Concomitant drugs | ||||||||||||
| Antihypertensive | 34 (24.3) | 39 (31.0) | 40 (32.8) | 55 (39.3) | 55 (41.0) | 58 (44.6) | 36 (33.0) | 39 (41.1) | 37 (42.5) | 86 (53.4) | 83 (54.2) | 79 (55.6) |
| Diuretic | 5 (3.6) | 9 (7.1) | 8 (6.6) | 8 (5.7) | 7 (5.2) | 9 (6.9) | 5 (4.6) | 6 (6.3) | 7 (8.0) | 18 (11.2) | 14 (9.2) | 14 (9.9) |
| α‐blocker | 2 (1.4) | 2 (1.6) | 2 (1.6) | 4 (2.9) | 2 (1.5) | 3 (2.3) | 0 (0) | 1 (1.1) | 3 (3.4) | 5 (3.1) | 5 (3.3) | 3 (2.1) |
| β‐blocker | 5 (3.6) | 6 (4.8) | 5 (4.1) | 5 (3.6) | 4 (3.0) | 4 (3.1) | 7 (6.4) | 8 (8.4) | 9 (10.3) | 9 (5.6) | 9 (5.9) | 9 (6.3) |
| CCB | 28 (20.0) | 30 (23.8) | 32 (26.2) | 46 (32.9) | 49 (36.6) | 49 (37.7) | 30 (27.5) | 30 (31.6) | 31 (35.6) | 66 (41.0) | 67 (43.8) | 64 (45.1) |
| ACE inhibitor | 2 (1.4) | 2 (1.6) | 2 (1.6) | 4 (2.9) | 4 (3.0) | 5 (3.8) | 0 (0) | 0 (0) | 0 (0) | 6 (3.7) | 5 (3.3) | 4 (2.8) |
| ARB | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.6) | 1 (0.7) | 1 (0.7) |
| Potassium‐sparing diuretic | 1 (0.7) | 1 (0.8) | 0 (0) | 1 (0.7) | 1 (0.7) | 1 (0.8) | 1 (0.9) | 1 (1.1) | 0 (0) | 4 (2.5) | 4 (2.6) | 4 (2.8) |
| Lipid‐lowering drug | 34 (24.3) | 30 (23.8) | 31 (25.4) | 48 (34.3) | 49 (36.6) | 49 (37.7) | 25 (22.9) | 25 (26.3) | 23 (26.4) | 37 (23.0) | 40 (26.1) | 40 (28.2) |
| Antidiabetic drug | 14 (10.0) | 12 (9.5) | 12 (9.8) | 16 (11.4) | 16 (11.9) | 15 (11.5) | 6 (5.5) | 7 (7.4) | 7 (8.0) | 16 (9.9) | 16 (10.5) | 16 (11.3) |
| Other | 51 (36.4) | 48 (38.1) | 50 (41.0) | 72 (51.4) | 70 (52.2) | 69 (53.1) | 63 (57.8) | 56 (58.9) | 50 (57.5) | 98 (60.9) | 98 (64.1) | 89 (62.7) |
| Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; ISH, isolated systolic hypertension; OLM, olmesartan medoxomil; SDH, systolic‐diastolic hypertension. Values are mean ± SD or No. (%). | ||||||||||||